Bierer L M, Aisen P S, Davidson M, Ryan T M, Schmeidler J, Davis K L
Department of Psychiatry, Mount Sinai School of Medicine, New York, N.Y.
Dementia. 1994 Sep-Oct;5(5):243-6. doi: 10.1159/000106731.
To assess the feasibility of one approach to combined cholinergic/noradrenergic treatment in Alzheimer's disease, ten patients were enrolled in a 2-week placebo-controlled study of oral physostigmine plus clonidine. The Alzheimer's Disease Assessment Scale (ADAS) was used as the primary outcome measure. Neither physostigmine alone, nor the combination of physostigmine plus clonidine, was associated with a statistically significant improvement for the group. Three patients did show an improvement of at least 4 points on the total ADAS score with the drug combination. The implications of these results for treatment strategies are discussed.
为评估一种用于阿尔茨海默病的胆碱能/去甲肾上腺素能联合治疗方法的可行性，10名患者参与了一项为期2周的口服毒扁豆碱加可乐定的安慰剂对照研究。阿尔茨海默病评估量表（ADAS）被用作主要结局指标。单独使用毒扁豆碱以及毒扁豆碱加可乐定的联合用药，均未使该组患者出现具有统计学意义的改善。有3名患者在使用联合药物治疗后，ADAS总分至少提高了4分。本文讨论了这些结果对治疗策略的意义。
